Stock Price
6.87
Daily Change
-6.15%
Yearly
-51.24%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AcelRx Pharmaceuticals 0.58 -0.04 -5.81% -62.04%
Adma Biologics 1.29 -0.07 -5.15% -35.50%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Aerie Pharmaceuticals 10.22 -0.14 -1.35% -19.97%
Alnylam Pharmaceuticals 171.36 -11.49 -6.28% 32.26%
Alexion Pharmaceuticals 182.50 0 0% 70.54%
BioMarin Pharmaceutical 82.95 -1.73 -2.04% 4.20%
Cytokinetics 35.50 -2.65 -6.95% 107.36%
Dynavax Technologies 13.17 -1.53 -10.41% 155.23%
Five Prime Therapeutics 38.00 0 0% 1,339.39%
Gilead Sciences 69.56 -0.11 -0.16% 13.00%
Knight Therapeutics Inc 5.21 -0.04 -0.76% -1.33%
Heron Therapeutics 8.68 -0.68 -7.27% -50.60%
Intercept Pharmaceuticals 15.63 -1.41 -8.27% -55.85%
Insmed 25.89 -1.07 -3.97% -35.50%
MacroGenics 16.40 -0.93 -5.37% -31.67%
Mirati Therapeutics 132.35 -4.71 -3.44% -43.26%
Omeros 6.87 -0.45 -6.15% -51.24%
Pacira 52.53 -1.22 -2.27% -13.33%
PDL BioPharma 2.47 0 0% -23.05%
Pfizer 54.27 1.23 2.32% 34.53%
Regulus Therapeutics 0.34 -0.03 -6.85% -55.05%
Rockwell Medical 0.38 -0.03 -7.45% -67.42%
Sangamo BioSciences 8.10 -0.35 -4.14% -18.92%
Sarepta Therapeutics 78.50 -4.69 -5.64% -50.36%
United Therapeutics 185.99 -3.30 -1.74% 39.35%
Vertex Pharmaceuticals 203.81 -0.64 -0.31% -10.73%
Immunic Inc. 8.32 -0.20 -2.35% -54.13%
Xoma 20.38 -1.82 -8.20% -38.22%

Indexes Price Day Year
US2000 2159 -47.02 -2.13% 14.10%
NASDAQ 15085 -295.85 -1.92% 21.03%

Omeros
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.